智通财经APP讯，华海药业(600521.SH)发布公告，公司下属控股子公司上海华奥泰生物药业股份有限公司(以下简称“华奥泰”)与Almirall,S.A.(以下简称“ALM”)达成全球研究合作及许可协议，用于开发具有多种潜在适应症(包括医学皮肤科)的新靶点的单克隆抗体候选药物。
根据协议，华奥泰拥有在中国开发和商业化项目和产品的权利，ALM拥有在中国以外的全球开发和商业化项目和产品的权利。利用创新研发平台，华奥泰将开展相关研究，直至获得具有临床概念验证的分子，ALM将向华奥泰支付总额不超过3.4亿美元的首付款、开发和商业化里程碑付款，以及相应的分级特许权使用费。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.